• PMD160 - PRICING OF REIMBURSED MEDICAL DEVICES IN FRANCE- WHAT FACTORS IMPACT DECISION-MAKING?

    Oct 1, 2018, 00:00

  • PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA

    Oct 1, 2018, 00:00

  • PSY30 - INCIDENCE AND PREVALENCE OF NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN US MEDICARE, 2008-2015

    Oct 1, 2018, 00:00

  • PMS32 - ASSESSING DIRECT AND INDIRECT HEALTH SYSTEM COSTS OF THE BUILD BETTER BONES WITH EXERCISE PILOT TRIAL

    Oct 1, 2018, 00:00

  • PRS105 - THE ASSESSMENT THE HEALTH UTILITIES INDEX IN CHILDREN WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA, RECEIVING OMALIZUMAB

    Oct 1, 2018, 00:00

  • PCN277 - PREDICTORS OF HOSPITALIZATIONS AND EMERGENCY DEPARTMENT (ED) VISITS IN SECOND-LINE (2L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

    Oct 1, 2018, 00:00

  • PND90 - THE IMPACT OF MINISTRY OF FOOD AND DRUG SAFETY (MFDS) SAFETY NOTICE ON THE USE OF METOCLOPRAMIDE IN KOREA- A POPULATION-BASED STUDY WITH AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PMD43 - BUDGET-IMPACT OF A NOVEL SURGICAL IMPLANT FOR PRIMARY OPEN-ANGLE GLAUCOMA FROM A UK HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD158 - REIMBURSEMENT POLICIES AFFECT PATIENT MIGRATION

    Oct 1, 2018, 00:00

  • PMU97 - OLDER ADULTS SATISFACTION WITH PHARMACEUTICAL CARE IN AN OUTPATIENT PHARMACY OF A NIGERIAN TEACHING HOSPITAL

    Oct 1, 2018, 00:00

  • PCP49 - EXPLORING THE SENSITIVITY TO CHANGE OF THE SAMANTA QUESTIONNAIRE IN HEAVY MENSTRUAL BLEEDING- THE SAMIRA STUDY

    Oct 1, 2018, 00:00

  • PCN254 - TRENDS IN BRCA TESTING OVER TIME AND SOCIOECONOMIC DEPRIVATION

    Oct 1, 2018, 00:00

  • PHP338 - PATIENT INVOLVEMENT IN CLINICAL PRACTICE GUIDELINE DEVELOPMENT PROCESSES- DOES REALITY ALIGN WITH INTENT?

    Oct 1, 2018, 00:00

  • PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA

    Oct 1, 2018, 00:00

  • PHP184 - PATIENT INFLUENCE ON BIOSIMILAR UPTAKE- THE NOCEBO EFFECT

    Oct 1, 2018, 00:00

  • PMS104 - EFFICIENCY EXAMINATION OF FUNCTIONAL ELECTRICAL STIMULATION IN THE REHABILITATION OF GAIT AMONG POST-STROKE PATIENTS

    Oct 1, 2018, 00:00

  • PRM94 - ALIGNING TEXT MINING AND MACHINE LEARNING ALGORITHMS WITH BEST PRACTICES FOR STUDY SELECTION IN SYSTEMATIC LITERATURE REVIEWS

    Oct 1, 2018, 00:00

  • PP1 - CONSIDERATIONS FOR USING A WEB-BASED SYSTEM TO COLLECT PATIENT-REPORTED OUTCOME (PRO) DATA

    Oct 1, 2018, 00:00

  • PRM250 - THE ANALYSIS OF ONCOLOGICAL PATIENT DETECTION IN MOSCOW

    Oct 1, 2018, 00:00

  • PND6 - CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PHP166 - TOOLS OF THE TRADE- PAYER APPROACHES TO HIGH PATIENT VOLUME, PREMIUM PRICED THERAPIES

    Oct 1, 2018, 00:00

  • PND86 - ECONOMIC BENEFITS ON ADULT UPPER LIMB SPASTICITY TREATMENT WITH ABOBOTULINUMTOXIN-A COMPARED TO ONABOTULINUMTOXIN-A OR INCOBOTULINUMTOXIN-A- ANALYSES IN A REAL-LIFE SETTING IN FRANCE

    Oct 1, 2018, 00:00

  • PCV90 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL HIP REPLACEMENT SURGERY- SYSTEMATIC REVIEW, NETWORK META-ANALYSIS AND COST –UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PDB127 - APPLICATION OF BEST WORST SCALING TO IMPROVE PATIENT-CENTERED TREATMENT DECISIONS IN DIABETIC PERIPHERAL NEUROPATHY

    Oct 1, 2018, 00:00

  • PRM81 - AN APPLICATION OF ARTIFICIAL INTELLIGENCE-BASED METHODOLOGY IN LITERATURE REVIEWS

    Oct 1, 2018, 00:00

  • PHP231 - ADOPTION OF INNOVATIONS IN THE GERMAN DRG-SYSTEM – A QUANTITATIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PMD166 - REVIEW OF NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME (MTEP) FOR MEDICAL DEVICES

    Oct 1, 2018, 00:00

  • PMD172 - HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN FRANCE- A COLLABORATION WITH MEDICAL DEVICE MANUFACTURERS OR NATIONAL AGENCY?

    Oct 1, 2018, 00:00

  • PRM95 - DETECTING INCIDENTS OF INJECTION FROM ELECTRONIC MEDICAL RECORDS USING MACHINE LEARNING METHODS

    Oct 1, 2018, 00:00

  • PMS44 - COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT

    Oct 1, 2018, 00:00

  • PSY94 - COST-EFFECTIVENESS MODEL COMPARING THERAPEUTIC STRATEGIES FOR TREATING IRON DEFICIENCY ANAEMIA (IDA) IN INFLAMMATORY BOWEL DISEASE (IBD)

    Oct 1, 2018, 00:00

  • PCN52 - PREVALENCE AND INCIDENCE OF DIFFERENT TYPES OF CANCER IN GERMANY- AN EPIDEMIOLOGICAL ANALYSIS BASED ON CLAIMS DATA OF MORE THAN 2.9 MILLION INSURED PERSONS

    Oct 1, 2018, 00:00

  • PRM68 - IMPUTATION METHODS FOR MISSING DATA IN COST-UTILITY ANALYSES ALONGSIDE RANDOMIZED CONTROLLED TRIALS- AGGREGATE OR NON-AGGREGATE?

    Oct 1, 2018, 00:00

  • PRM16 - AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) LEVEL PREDICTION IN POPULATION-BASED ADMINISTRATIVE DATABASES IN THE ABSENCE OF RECORDED LABORATORY VALUES

    Oct 1, 2018, 00:00

  • PCV19 - PATTERNS OF ANTICOAGULATION CONTROL AND CLINICAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS- A REAL-WORLD STUDY USING POPULATION-BASED DATA AND GROUP-BASED TRAJECTORY MODELS

    Oct 1, 2018, 00:00

  • PHP152 - MECHANISMS OF ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLAND

    Oct 1, 2018, 00:00

  • PSS9 - DRUGS UTILISATION IN THE ITALIAN SETTING- THE CASE OF WAMD, DME AND RVO

    Oct 1, 2018, 00:00

  • PMS109 - PREVENTION OF SHOULDER JOINT INJURIES IN WATER POLO WITH STRETCHING AND STABILIZATION TECHNIQUES

    Oct 1, 2018, 00:00

  • PMS76 - HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH REFRACTORY MYASTHENIA GRAVIS (MG), IN COMPARISON TO NON-REFRACTORY MG PATIENTS IN ENGLAND- A RETROSPECTIVE COHORT STUDY.

    Oct 1, 2018, 00:00

  • PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANY

    Oct 1, 2018, 00:00

  • PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SET

    Oct 1, 2018, 00:00

  • PCV119 - BASELINE HEALTH RELATED QUALITY OF LIFE IN PATIENTS ADMITTED BY HEART FAILURE. DOES GENDER MATTER?

    Oct 1, 2018, 00:00

  • PND119 - SURVEY ANALYSIS OF TREATMENT WITH INTERFERON BETA 1A IN BRAZIL AMONG MS PATIENTS PARTICIPATING IN A PATIENT SUPPORT PROGRAM (PSP)

    Oct 1, 2018, 00:00

  • PMU89 - EUROPEAN UNION 5 (EU5) NORMS FOR THE 3-LEVEL EQ-5D (EQ-5D-3L) QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PND146 - MS PATIENTS’ PERCEPTION OF THE EFFECTS OF PR-FAMPRIDINE ON WALKING DISORDERS AND DAILY LIFE- RESULTS FROM AN OBSERVATIONAL STUDY CONDUCTED VIA AN ONLINE PATIENT COMMUNITY

    Oct 1, 2018, 00:00

  • PMS112 - PATIENT AND RHEUMATOLOGIST PREFERENCES FOR THE ATTRIBUTES OF RHEUMATOID ARTHRITIS TREATMENTS IN SPAIN. A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PGI22 - COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY

    Oct 1, 2018, 00:00

  • PND122 - HEALTH STATE UTILITIES ASSOCIATED WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS), A RARE GENETIC DISORDER

    Oct 1, 2018, 00:00

  • PMU40 - LIVE BIRTH RATE (LBR), ONGOING PREGNANCY RATE (OPR) AND OVARIAN HYPERSTIMULATION SYNDROME (OHSS) RISK WITH ORIGINATOR VERSUS BIOSIMILAR RECOMBINANT FOLLITROPIN ALFA- A POOLED ANALYSIS OF CLINICAL TRIAL DATA

    Oct 1, 2018, 00:00

  • PSS62 - TREATMENT PREFERENCE DRIVERS OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Oct 1, 2018, 00:00

  • PRM87 - CRITICAL EVALUATION OF VARIOUS DATA MINING ALGORITHMS USED FOR SIGNAL DETECTION IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PMU73 - EVIDENCE MAP OF ECONOMIC EVALUATIONS OF EXERCISE THERAPY PUBLISHED SINCE 2015

    Oct 1, 2018, 00:00

  • PHP245 - UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Oct 1, 2018, 00:00

  • PHP115 - COMPARATIVE ANALYSIS OF THE MARKET PENETRATION OF PERSONALISED MEDICINE DRUGS UNDER THE CONDITIONS OF AMNOG

    Oct 1, 2018, 00:00

  • PHP22 - IS THE EUROPEAN BIOSIMILAR MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT, AND PRICING

    Oct 1, 2018, 00:00

  • PRS85 - VALIDATION OF AN EASY-TO-COMPLETE QUESTIONNAIRE FOR STUDYING PREDICTORS OF ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Oct 1, 2018, 00:00

  • PHP52 - ACCESSIBILITY AND ACCESS TO ORPHAN DRUGS IN PORTUGAL- HOW FAR ARE WE?

    Oct 1, 2018, 00:00

  • PND140 - IMPACT OF MIGRAINE ON WORK PRODUCTIVITY IN PORTUGUESE PATIENTS

    Oct 1, 2018, 00:00

  • PCP52 - AN ANALYTICAL FRAMEWORK FOR EFFICACY EVALUATION OF LIGHT THERAPY IN MOOD DISORDERS- THE LINKED MECHANISMS APPROACH

    Oct 1, 2018, 00:00

  • PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTS

    Oct 1, 2018, 00:00

  • PSY102 - MUCOPOLYSACCHARIDOSIS DRUG COVERAGE IN RUSSIA- EXPEDIENCY OF DRUG PROCUREMENT CENTRALIZATION

    Oct 1, 2018, 00:00

  • PMS75 - SEEKING THE STATE OF THE ART IN STANDARDIZED MEASUREMENT OF HEALTH CARE RESOURCE USE AND COSTS IN JUVENILE IDIOPATHIC ARTHRITIS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PMS17 - BUDGET IMPACT OF DENOSUMAB IN THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMU3 - SELF MEDICATION ATTITUDE, KNOWLEDGE, AND PERCEPTION

    Oct 1, 2018, 00:00

  • PUK14 - LOW-DOSE ORAL DESMOPRESSIN LYOPHILISATE IS A COST-EFFECTIVE TREATMENT OPTION FOR PATIENTS EXPERIENCING AT LEAST TWO NOCTURNAL MICTURITIONS

    Oct 1, 2018, 00:00

  • PHP219 - MEDICINRÅDET AND THE NEW HOSPITAL DRUG APPRAISAL PROCESS IN DENMARK – THE STORY SO FAR

    Oct 1, 2018, 00:00

  • PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.

    Oct 1, 2018, 00:00

  • PHP347 - REGULATORY, POLICY AND OPERATIONAL BARRIERS TO OUTCOME-BASED RISK SHARING AGREEMENTS IN THE U.S. MARKET- OPPORTUNITIES FOR REFORM

    Oct 1, 2018, 00:00

  • PRM100 - WEIGHTED METHOD FOR ESTIMATING INCIDENCE OF HERPES ZOSTER IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PMD41 - THE BUDGET IMPACT AND COST-CONSEQUENCE OF TREATING DIABETIC FOOT ULCERS WITH URGOSTART

    Oct 1, 2018, 00:00

  • PRM148 - HEALTH TECHNOLOGY ASSESSMENT AGENCY APPRAISAL OF IMMUNO-ONCOLOGY CURE FRACTION SURVIVAL MODELLING

    Oct 1, 2018, 00:00

  • PHP61 - THE NEW AIFA INNOVATION FRAMEWORK TO RECOGNIZE INNOVATIVE DRUGS- A PRELIMINARY ANALYSIS OF KEY DRIVERS OF EVALUATION

    Oct 1, 2018, 00:00

  • PCN257 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) FOLLOWING INITIAL PLATINUM THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)- A MEDICAL RECORD REVIEW IN GERMANY

    Oct 1, 2018, 00:00

  • PND63 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

    Oct 1, 2018, 00:00

  • PHP251 - PUBLIC-PRIVATE CONTRIBUTION TO BIOPHARMACEUTICAL DISCOVERIES- A BIBLIOMETRIC ANALYSIS OF BIOMEDICAL RESEARCH IN UK

    Oct 1, 2018, 00:00

  • PRS98 - SLEEP DISTURBANCE AND FATIGUE AS CONSEQUENCES OF COUGH AND MUCUS PRODUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE- INSIGHTS FROM A PATIENT ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • PRM121 - COMPARATIVE IMPACT OF TWO VARICELLA VACCINES ON VARICELLA EPIDEMIC DYNAMICS IN ITALY

    Oct 1, 2018, 00:00

  • PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIES

    Oct 1, 2018, 00:00

  • PND83 - HEALTH RESOURCE UTILIZATION ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PCP43 - HEALTH IMPACT MODELLING (HIM)- CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

    Oct 1, 2018, 00:00

  • PRS28 - COST OF ILLNESS DUE TO BACTERIAL PNEUMONIA IN THE ADULT POPULATION IN DOMINICAN REPUBLIC FROM A PUBLIC PERSPECTIVE DURING 2018

    Oct 1, 2018, 00:00

  • DS3 - REGORAFENIB IN METASTATIC COLORECTAL CANCER- COST-EFFECTIVENESS ANALYSIS BASED ON PROPENSITY SCORE WEIGHTED COHORT OF CZECH REGISTRY

    Oct 1, 2018, 00:00

  • PCP14 - VALUE FRAMEWORKS AND PRICING SETTING; CAN THEY CO-EXIST?

    Oct 1, 2018, 00:00

  • PRM231 - REPORT OF NETWORK META-ANALYSIS GEOMETRY- A SYSTEMATIC REVIEW AND METRICS RECOMMENDATION

    Oct 1, 2018, 00:00

  • PHP282 - NEW AIFA INNOVATION ALGORITHM- IS IT REALLY A STEP FORWARD IN ALIGNING AIFA’S DECISION WITH EUROPEAN HTAS?

    Oct 1, 2018, 00:00

  • PRM138 - THE DIVE FRAMEWORK FOR USING DIFFERENT TYPES OF INFORMATION IN ESTIMATING LIFETIME CLINICALLY PLAUSIBLE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PRM1 - VALIDATION OF ALTERNATIVE “SURROGATE” CLINICAL ENDPOINTS IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PIN45 - COST-EFFECTIVENESS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS

    Oct 1, 2018, 00:00

  • Unique Review Criteria and Patient and Stakeholder Reviewers- Analysis of PCORI’s Approach to Research Funding

    Oct 1, 2018, 00:00

  • PND118 - PERCEPTIONS AND NEEDS OF PATIENTS WITH MIGRAINE IN GREECE- A FOCUS GROUP STUDY

    Oct 1, 2018, 00:00

  • PHP168 - TRUMP’S PLANS TO REDUCE DRUG PRICES- FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRST

    Oct 1, 2018, 00:00

  • PRS33 - THE CLINICAL AND ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS IN ALGERIA

    Oct 1, 2018, 00:00

  • PHP134 - THE CHALLENGES OF PHARMACEUTICAL INDUSTRY IN IRAN; THEIR ROOTS, RANKS, AND RESOLUTIONS

    Oct 1, 2018, 00:00

  • PRM85 - MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING TO POWER LITERATURE SEARCH FOR TIMELY, MEANINGFUL RESULTS

    Oct 1, 2018, 00:00

  • PDB65 - THE COST-EFFECTIVENESS OF METFORMIN IN PRE-DIABETICS- A SYSTEMATIC LITERATURE REVIEW OF HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PRM53 - THE USE OF PROXY MARKERS TO DEFINE DISEASE STAGE IN PATIENTS WITH MALIGNANT MELANOMA- AN OBSERVATIONAL STUDY USING THE HOSPITAL EPISODE STATISTICS (HES) DATABASE IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM259 - THE CHALLENGES OF ESTIMATING MULTI-STATE MODEL TRANSITIONS IN RARE DISEASES- INFORMING AN ECONOMIC DECISION MODEL FOR DUCHENNE MUSCULAR DYSTROPHY

    Oct 1, 2018, 00:00

  • PRM36 - COST-EFFECTIVENESS AND BUDGET IMPACT THRESHOLDS IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PSS29 - SECUKINUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD1 - POST-ND-YAG LASER COMPLICATIONS IN CATARACT PATIENTS TREATED FOR POSTERIOR CAPSULAR OPACIFICATION- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY108 - COST-UTILITY ANALYSIS OF TOCILIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF GIANT CELL ARTERITIS IN ITALIAN PATIENTS

    Oct 1, 2018, 00:00

  • PND73 - THE IMPACT OF MODELLING SUBSEQUENT TREATMENT ON ESTIMATES OF COST-EFFECTIVENESS- AN ANALYSIS OF DISEASE-MODIFYING TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PRM89 - DATABASE ANALYSIS OF A PSP (PATIENT SUPPORT PROGRAM) FOR PATIENTS USING INTERFERON BETA-1A FOR RELAPSING MULTIPLE SCLEROSIS IN BRAZIL

    Oct 1, 2018, 00:00

  • PCN239 - NICE AND THE CANCER DRUGS FUND- APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN262 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH LUNG CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PRM51 - A NEW CONCEPTUAL MODEL OF THE COST-EFFECTIVENESS THRESHOLD

    Oct 1, 2018, 00:00

  • PSY219 - HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMU49 - HEALTH INSURANCE COST OF PSORIASIS IN HUNGARY- COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN’S HEALTH QUESTIONNAIRE AGAINST THE ...

    Oct 1, 2018, 00:00

  • PIH34 - PROGRAM 75+ - FREE MEDICINES FOR THE ELDERLY

    Oct 1, 2018, 00:00

  • PMH35 - ECONOMIC BURDEN OF SCHIZOPHRENIA IN EUROPE

    Oct 1, 2018, 00:00

  • PMS117 - A MULTIDSCIPLINARY STUDY ON HEALTH-RELATED QUALITY OF LIFE IN CLUBFOOT

    Oct 1, 2018, 00:00

  • PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION- ANALYTICS FOR EUROPE

    Oct 1, 2018, 00:00

  • PCN126 - DIRECT COST STUDY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN297 - IMPACT OF ECONOMIC SANCTIONS ON ACCESS TO NONCOMMUNICABLE DISEASES MEDICINES IN THE ISLAMIC REPUBLIC OF IRAN

    Oct 1, 2018, 00:00

  • PRM211 - MITIGATING EMOTIONAL BURDEN OF CONDUCTING INTERVIEWS WITH PEDIATRIC PATIENTS AND/OR THEIR CAREGIVERS ON THE INTERVIEWER- FIRST-PERSON INTERVIEWER EXPERIENCES

    Oct 1, 2018, 00:00

  • PSS51 - ANALYSIS OF TOPICAL PREPARATIONS FOR TREATMENT OF ONYCHOMYCOSIS IN UKRAINE

    Oct 1, 2018, 00:00

  • MD2 - NETWORK META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY STUDIES ALLOWING FOR MULTIPLE TESTS AT MULTIPLE THRESHOLDS FOR HEALTHCARE POLICY AND DECISION MAKING

    Oct 1, 2018, 00:00

  • PSY104 - CORE OBESITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF WEIGHT MANAGEMENT INTERVENTIONS

    Oct 1, 2018, 00:00

  • PMD79 - COST-EFFECTIVENESS OF ULTRASOUND-GUIDED CENTRAL VENOUS CATHETERISATION FROM THE GERMAN PAYER PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PCN48 - REAL-WORLD TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PMS78 - CHANGES IN THE PRICES OF INCUMBENT TNF-ALPHA INHIBITORS FOLLOWING THE MARKET ENTRY OF COMPETITORS

    Oct 1, 2018, 00:00

  • PSS69 - APPRAISAL OF PATIENT REPORTED OUTCOME INSTRUMENTS IN INFLAMMATORY ACNE

    Oct 1, 2018, 00:00

  • PRM19 - REPORTING FOLLOW-UP IN SURVIVAL ANALYSES- INFORMATIVE OR NOT?

    Oct 1, 2018, 00:00

  • PRM152 - A GENERIC BAYESIAN DES MODEL FOR MULTI-STATE DISEASE PROGRESSION

    Oct 1, 2018, 00:00

  • PRM28 - PERFORMANCE OF THE EARLY WARNING SYSTEM VITAL TO PREDICT UNANTICIPATED HIGHER-LEVEL OF CARE ADMISSION AND IN-HOSPITAL DEATH OF WARD PATIENTS

    Oct 1, 2018, 00:00

  • PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELAND

    Oct 1, 2018, 00:00

  • PHP215 - DANISH MEDICINE COUNCIL PROCESS OF ASSESSING NEW HOSPITAL MEDICINES– FIRST YEAR OF IMPLEMENTATION

    Oct 1, 2018, 00:00

  • PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PMU41 - PAST, CURRENT AND EXPECTED NEED FOR HOME ARTIFICIAL NUTRITION IN PIEDMONT- RESOURCES NEEDED TO MAINTAIN A RECOGNIZED HIGH QUALITY LEVEL

    Oct 1, 2018, 00:00

  • PSY109 - WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE

    Oct 1, 2018, 00:00

  • PND149 - FACTORS ASSOCIATED WITH THE CAREGIVERS’ INTENTION TO INSTITUTIONALIZE PERSONS WITH DEMENTIA

    Oct 1, 2018, 00:00

  • PDB103 - FINANCIAL ACCESS TO HEALTH CARE USE IN DIABETICS WITH HIGH-DEDUCTIBLE HEALTH PLAN (HDHP)

    Oct 1, 2018, 00:00

  • PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMU104 - WHAT ARE THE VIEWS AND PERCEPTIONS OF THE GREEK POPULATION TOWARDS THE PHARMACEUTICAL INDUSTRY?

    Oct 1, 2018, 00:00

  • PSY79 - THE COST OF MAJOR BLEEDING EVENTS ASSOCIATED WITH ANTICOAGULATION TREATMENT – AN ESTIMATION OF THE CONTRIBUTION OF THE REVERSAL AGENTS TO THE OVERALL COST OF MAJOR BLEEDING IN A UK SETTING

    Oct 1, 2018, 00:00

  • PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PMH46 - A NATIONAL COMPREHENSIVE SURVEY STUDY OF PARKINSON’S DISEASE PSYCHOSIS PATIENTS AND CAREGIVERS REGARDING TIME TO PARKINSON’S DISEASE PSYCHOSIS DIAGNOSIS AND TREATMENT INITIATION

    Oct 1, 2018, 00:00

  • PMD56 - COST OF STENT-RETRIEVER MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGAL

    Oct 1, 2018, 00:00

  • PSS4 - IMPORTANCE OF PROPERLY ADJUSTING FOR HETEROGENEITY AMONG NETWORK META-ANALYSES CONSIDERING OUTCOMES WITH MULTIPLE PRE-DEFINED LEVELS- AN ILLUSTRATIVE EXAMPLE IN PSORIASIS

    Oct 1, 2018, 00:00

  • PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PDB39 - EMPAGLIFLOZIN FOR PATIENTS IN THE NETHERLANDS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE- A BUDGET IMPACT MODEL

    Oct 1, 2018, 00:00

  • PRM233 - THE USE OF THE TWO-STAGE METHOD IN ADJUSTING FOR TREATMENT CROSSOVER. A SIMULATION STUDY.

    Oct 1, 2018, 00:00

  • PRS104 - USING OF "THE FOOD HYPERSENSITIVITY FAMILY IMPACT” (FLIP) QUESTIONNAIRE FOR ASSESSMENT OF QUALITY OF LIFE OF FOOD-ALLERGIC CHILD'S FAMILY MEMBERS.

    Oct 1, 2018, 00:00

  • PCN200 - COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE

    Oct 1, 2018, 00:00

  • PCN372 - EVIDENCE MAP OF PATIENT REPORTED OUTCOME STUDIES IN NON-HODGKIN LYMPHOMA SINCE 1960

    Oct 1, 2018, 00:00

  • PND157 - ENHANCEMENT FOR STROKE PATIENT’S OUTCOMES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PHP230 - EU5 MARKET ACCESS FOR MEDICINES APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES

    Oct 1, 2018, 00:00

  • PCV118 - FACTORS DETERMINING SELECTION OF APPROPRIATE PATIENTS FOR PCSK9 INHIBITORS IN EUROPEAN CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIAL

    Oct 1, 2018, 00:00

  • PHP198 - EVALUATION OF THE SWEDISH EARLY AWARENESS AND ALERT SYSTEM

    Oct 1, 2018, 00:00

  • PIN129 - ADAPTING INFLUENZA PATIENT-REPORTED OUTCOMES (PRO) MEASURES TO MONITOR RESPIRATORY SYNCYTIAL VIRUS (RSV) SYMPTOM SEVERITY IN ADULTS- QUALITATIVE EVIDENCE OF KEY CONCEPTS AND CONTENT VALIDITY

    Oct 1, 2018, 00:00

  • PSY89 - COSTS AND EFFECTS OF ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA- A PROSPECTIVE COHORT STUDY IN ITALY

    Oct 1, 2018, 00:00

  • PSS53 - ORIGINATOR AND GENERIC MARKET ACCESS PROTECTION STRATEGIES IN GERMANY USING DERMATOLOGY AS AN EXAMPLE

    Oct 1, 2018, 00:00

  • PGI23 - COST-EFFECTIVENESS ANALYSIS OF PARENTERAL METHOTREXATE FOR THE TREATMENT OF CROHN’S DISEASE IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PRM225 - EVALUATING PREVIOUS MIGRAINE HEADACHE FREQUENCY STATISTICAL MODELLING APPROACHES USING AN INDEPENDENT DATASET FROM THE EVOLVE STUDIES IN EPISODIC MIGRAINE

    Oct 1, 2018, 00:00

  • PCV93 - COST-EFFECTIVENESS OF GUIDELINE ADHERENCE IN CORONARY PATIENTS- THE IMPACT OF THE METHODOLOGY

    Oct 1, 2018, 00:00

  • PRM108 - EVALUATION OF CATARACT TREATMENT IN THE UNITED KINGDOM USING A PATIENT PATHWAY DISCREET EVENT SIMULATION MODEL

    Oct 1, 2018, 00:00

  • PCV84 - COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS

    Oct 1, 2018, 00:00

  • PCN343 - KNOWLEDGE ABOUT HUMAN PAPILLOMAVIRUS (HPV) IN PARENTS OF TEENAGE BOYS IN HUNGARY

    Oct 1, 2018, 00:00

  • PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY

    Oct 1, 2018, 00:00

  • PND89 - BLOOD LOSS AND TRANSFUSION MANAGEMENT IN COMPLEX MULTI-LEVEL SPINE SURGERY IN EUROPE

    Oct 1, 2018, 00:00

  • PMS55 - THE EFFECTS OF MORTALITY ASSUMPTIONS ON THE COST EFFECTIVENESS OF A NEW GOUT TREATMENT

    Oct 1, 2018, 00:00

  • PRS65 - ASSESSING THE IMPACT OF CONCURRENT PRESCRIPTION OPIOID USE ON ADHERENCE TO MAINTENANCE MEDICATIONS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A RETROSPECTIVE CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PHP229 - EU5 MARKET ACCESS FOR MEDICINES WITH CONDITIONAL MARKETING AUTHORISATIONS

    Oct 1, 2018, 00:00

  • PMS93 - ASSESSMENT OF PATIENTS’ ADHERENCE ON MTX USE- A PATIENT ASSOCIATION SURVEY.

    Oct 1, 2018, 00:00

  • PIN70 - INVESTIGATING THE SECONDARY CARE SYSTEM BURDEN OF INFLUENZA HOSPITALISATION IN CLINICAL RISK GROUPS USING THE HES DATABASE

    Oct 1, 2018, 00:00

  • PRS40 - COST-EFFECTIVENESS OF THE SQ® GRASS SUBLINGUAL IMMUNOTHERAPY (SLIT) TABLET IN A PAEDIATRIC POPULATION

    Oct 1, 2018, 00:00

  • PMD67 - COST-CONSEQUENCE ANALYSIS OF A HEMOSTATIC FLOWABLE MATRIX ALONE OR IN COMBINATION FOR SPINE SURGERY PATIENTS

    Oct 1, 2018, 00:00

  • PCN22 - MARKETING AUTHORISATION PRACTICE OF THE EUROPEAN MEDICINES AGENCY (EMA) IN ONCOLOGICAL INDICATIONS

    Oct 1, 2018, 00:00

  • PND74 - COST UTILITY MODEL OF BRIVARACETAM IN THE ADJUNCTIVE TREATMENT FOR PARTIAL-ONSET EPILEPTIC SEIZURES IN SPAIN

    Oct 1, 2018, 00:00

  • PMS67 - DEVELOPMENT OF A PATIENT DECISION AID (PDA) FOR PATIENTS WITH RHEUMATOID ARTHRITIS THAT REDUCES DECISIONAL CONFLICT AND IMPROVES READINESS FOR TREATMENT DECISION MAKING

    Oct 1, 2018, 00:00

  • PCN57 - THE ASSOCIATION BETWEEN METFORMIN EXPOSURE AND SURVIVAL AMONG DIABETIC PATIENTS WITH NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • DS2 - EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSES OF DABIGATRAN VERSUS RIVAROXABAN IN NON-VALVULAR ATRIAL FIBRILLATION- A COHORT STUDY IN THE SNDS FRENCH NATIONWIDE CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PMD107 - COST-EFFECTIVENESS ANALYSIS OF NEXT GENERATION RENAL DENERVATION THERAPY DEVICES- THRESHOLD ANALYSIS AND PROJECTIONS OF THE SPYRAL HTN-ON MED TRIAL FOR GERMANY

    Oct 1, 2018, 00:00

  • PND97 - DEVELOPING STROKE SYSTEM CARE FOR LOW MIDDLE INCOME COUNTRIES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PMD109 - A CANADIAN COST-UTILITY ANALYSIS OF TWO TRABECULAR MICRO-BYPASS STENTS IMPLANTED AT TIME OF CATARACT SURGERY IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA

    Oct 1, 2018, 00:00

  • PRM90 - DIGITAL DASHBOARD FOR MAPPING PATIENT DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • PND153 - ANALYSIS OF RESPONSES TO SF-36V2 ITEMS FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PCN296 - BIG DATA ANALYSIS OF CANCER TREATMENT IN GERMANY - MAPPING OF TREATMENT LANDSCAPE BASED ON A GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN’S LYMPHOMA- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PMU67 - COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PSS42 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN MOROCCO

    Oct 1, 2018, 00:00

  • PIH9 - BACTERIOLOGICAL PROFILE AND ANTIBIOGRAM OF NEONATAL SEPSIS IN THE NEONATAL INTENSIVE CARE UNIT OF AN EGYPTIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PCN27 - THE REAL-WORLD COST AND EFFECTIVENESS OF EVEROLIMUS IN METASTATIC BREAST CANCER IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMD73 - ECONOMIC IMPACT OF THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA ON HIP FRACTURE- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-HN) STUDY

    Oct 1, 2018, 00:00

  • PMH74 - QUALITY OF LIFE ACCORDING TO TEMPORAL ILLICIT OPIOID USE AND RESPONDER RATE IN ADULTS RECEIVING BUPRENORPHINE DEPOT INJECTIONS (CAM2038) TO TREAT OPIOID USE DISORDER IN A 48-WEEK OPEN LABEL STUDY

    Oct 1, 2018, 00:00

  • PIN27 - COMMUNITY-ACQUIRED PNEUMONIA HOSPITALIZATION COSTS IN THE ADULT POPULATION OF COSTA RICA FROM A PUBLIC HEALTH PERSPECTIVE OVER A 10 YEAR PERIOD (2005-2014)

    Oct 1, 2018, 00:00

  • PHP343 - CLINICAL DEVELOPMENT OF BIOLOGICS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION, 2003-2016

    Oct 1, 2018, 00:00

  • PHP272 - QUANTITATIVE ASSESSMENT OF TECHNICAL ERRORS FOUND IN ECONOMIC MODELS SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PHP51 - UTILIZTION OF MONOCLONAL ANTIBODY IN CHINA- A STUDY FROM NATOINAL MARKET ACCESS VIEW

    Oct 1, 2018, 00:00

  • PIH28 - ISAACUS DATA LAKE PRE-PRODUCTION PROJECT- CHILD PLACEMENT DECISION AND ITS COST DRIVERS

    Oct 1, 2018, 00:00

  • PIN114 - ASSESSMENT OF THE EFFICACY AND SAFETY OF VORICONAZOLE, COMPARED WITH AVAILABLE THERAPIES IN THE TREATMENT OF PATIENTS WITH INVASIVE ASPERGILLOSIS- A NETWORD META-ANALYSIS

    Oct 1, 2018, 00:00

  • PND115 - A COMPARISON OF FDA AND EMA GUIDANCE ON MEDICINES FOR THE TREATMENT OF ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PHP208 - PHYSICIANS’ IMPROVEMENT SUGGESTIONS FOR ENTERAL NUTRTION CARE IN CHINA- A CROSS-SECTIONAL SURVEY

    Oct 1, 2018, 00:00

  • PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PSY12 - REAL-WORLD EFFECTIVENESS STUDY OF FERRIC CARBOXYMALTOSE IN ANAEMIC PATIENTS

    Oct 1, 2018, 00:00

  • PIN5 - 10 YEARS OF HUMAN PAPILLOMAVIRUS SYSTEMATIC VACCINATION IN SPAIN- FORECASTING HEALTH OUTCOMES CONSIDERING AS04-HPV16/18 VACCINE EFFECTIVENESS DATA

    Oct 1, 2018, 00:00

  • PCN146 - INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOCYTIC LEUKEMIA (ALL)- ESTABLISHING A VALUE-BASED COST – PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PMH78 - CARE BURDEN AND QUALITY OF LIFE OF PRIMARY CAREGIVERS OF CHILDREN WITH INTELLECTUAL DISABILITIES IN MONGOLIA- THE MEDIATING EFFECT OF FAMILY STRENGTH

    Oct 1, 2018, 00:00

  • PCN230 - ARE NICE AND THE SMC DIVERGING IN THEIR ASSESSMENT OF ONCOLOGY DRUGS?

    Oct 1, 2018, 00:00

  • PCP51 - OBSERVATIONAL STUDIES COLLECTING PATIENT PREFERENCES AND EXPERIENCES- REGULATORY DIFFERENCES ACROSS COUNTRIES IN EUROPE

    Oct 1, 2018, 00:00

  • PCN119 - SECONDARY CARE RESOURCE UTILIZATION AND COST OF CARE AMONG FINNISH NON-SMALL CELL LUNG CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PND102 - CARE PATHWAY DIVERSITY OF PATIENTS WITH MULTIPLE SCLEROSIS BETWEEN FRENCH REGIONS

    Oct 1, 2018, 00:00

  • PCN130 - COST ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) – A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANY

    Oct 1, 2018, 00:00

  • PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTING

    Oct 1, 2018, 00:00

  • PMD121 - EXPLORING THE DAILY CLINICAL PRACTICE IN MYOCARDIAL INFARCTION (MI) CARE IN EUROPE- SURVEY OF DIAGNOSTIC AND TREATMENT STRATEGIES FOR THEORETICAL PATIENTS

    Oct 1, 2018, 00:00

  • PCN173 - COST-EFFECTIVENESS OF NEW TRIPLET COMBINATIONS WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PMD78 - COST-EFFECTIVENESS ANALYSIS OF REAL TIME CONTINOUS GLUCOSE MONITORING (RT-CGM) VS SELF MONITORING BLOOD GLUCOSE (SMBG) IN PATIENTS WITH TYPE 1 DIABETES IN SPAIN

    Oct 1, 2018, 00:00

  • PMD82 - COST-EFFECTIVENESS OF INSULIN PUMP THERAPY IN ADULTS WITH TYPE 1 DIABETES MELLITUS (T1DM)- THE EMIPE STUDY - A REAL-LIFE EVIDENCE STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PND127 - QUALITY OF LIFE IN PAEDIATRIC MULTIPLE SCLEROSIS- SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMS64 - MULTIPLE SCLEROSIS AND WORKABILITY IN ITALY- THE ECONOMIC EFFECT OF NATALIZUMAB ON THE ABILITY TO WORK

    Oct 1, 2018, 00:00

  • PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)

    Oct 1, 2018, 00:00

  • PSY6 - EFFECTIVENESS AND SAFETY OF PEGVISOMANT- META-ANALYSIS OF OBSERVATIONAL LONGITUDINAL STUDIES

    Oct 1, 2018, 00:00

  • PMS51 - COST-EFFECTIVENESS OF TOFACITINIB-CONTAINING SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PSY45 - BUDGET IMPACT ANALYSIS OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE

    Oct 1, 2018, 00:00

  • PIN81 - PHARMACISTS AS VACCINATORS- FIRST YEAR EXPERIMENTATION ON SEASONAL INFLUENZA VACCINATION IN FRANCE

    Oct 1, 2018, 00:00

  • PMD129 - TRENDS IN OUTCOMES ASSOCIATED WITH ACUTE ISCHEMIC STROKE IN A US COMMERCIAL INSURANCE POPULATION

    Oct 1, 2018, 00:00

  • PCN394 - PRICES AND COSTS OF CANCER TREATMENTS IN FRANCE- REALITIES, CHALLENGES AND PERSPECTIVES

    Oct 1, 2018, 00:00

  • PHP239 - THE INTRODUCTION AND IMPLICATIONS OF THE COST-CONTAINMENT MEASURE ‘THE SLUICE’ FOR EXPENSIVE INNOVATIVE DRUGS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCV10 - RANDOMISED CONTROLLED TRIALS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) – A SYSTEMATIC REVIEW (SR) OF INCLUDED PATIENT POPULATIONS

    Oct 1, 2018, 00:00

  • PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIES

    Oct 1, 2018, 00:00

  • PRS4 - ASSOCIATIONS OF DEPRESSION AND ANXIETY WITH A RISK OF EXACERBATIONS IN ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP

    Oct 1, 2018, 00:00

  • PCN347 - EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS ...

    Oct 1, 2018, 00:00

  • PRM156 - THE IMPORTANCE OF ACCOUNTING FOR PARAMETER UNCERTAINTY AROUND THE SF-6D VALUE SETS AND ITS IMPACT ON STUDIES THAT USE THE SF-6D TO MEASURE HEALTH UTILITY

    Oct 1, 2018, 00:00

  • PMU80 - ENHANCING MEDICATION ADHERENCE THROUGH AN ADHERENCE SUPPORT PROGRAM

    Oct 1, 2018, 00:00

  • PIN69 - INDIRECT COSTS OF PNEUMOCOCCAL DISEASES IN POLAND- AN ANALYSIS BASED ON ABSENTEEISM DATA FROM SOCIAL INSURANCE INSTITUTION

    Oct 1, 2018, 00:00

  • PMU54 - HOW MUCH DOES IT COST TO TRAIN A PHYSICIAN IN COLOMBIA?

    Oct 1, 2018, 00:00

  • PCN327 - CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY- AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD

    Oct 1, 2018, 00:00

  • PND156 - THE IMPACT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) ON WORK- THE PATIENTS’ PERSPECTIVES

    Oct 1, 2018, 00:00

  • PHP304 - INTRODUCTION OF EBM IN MEDICAL PROFESSIONALS' EDUCATION IN BULGARIA, IN ASSOCIATION WITH THE HTA PROCESS - A PILOT STUDY

    Oct 1, 2018, 00:00

  • PRM266 - 50 MILLION TESTS AND CONFOUNDING- THE PROMISES AND CHALLENGES OF BIG DATA

    Oct 1, 2018, 00:00

  • PRM166 - CONCEPTUALIZING A CORE DISCRETE EVENT SIMULATION MODEL TO EVALUATE THE ECONOMIC IMPACT OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    Oct 1, 2018, 00:00

  • PRS103 - SMARTPHONE APPLICATION FOR THE ASTHMA RESEARCH IN CHILDREN AND ADOLESCENTS (ARCA) COHORT- A PILOT STUDY

    Oct 1, 2018, 00:00

  • PIN57 - ECONOMIC ASSESSMENT OF EFFECTIVENESS AND SAFETY OF COMMON PRACTICE PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS IN A MULTIDISCIPLINARY HOSPITAL

    Oct 1, 2018, 00:00

  • PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACA ...

    Oct 1, 2018, 00:00

  • PCN285 - PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES- A COMPARATIVE ASSESSMENT.

    Oct 1, 2018, 00:00

  • PMS36 - SWITCH PATTERNS AND TOTAL HEALTHCARE COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIATIC ARTHRITIS- RESULTS FROM A US CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PHP63 - MEASURES TO FIGHT ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLAND

    Oct 1, 2018, 00:00

  • PND50 - SOCIAL RETURN ON INVESTMENT OF AN IDEAL APPROACH TO MULTIPLE SCLEROSIS WITHIN THE SPANISH NATIONAL HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PDB18 - CLINICAL ECONOMIC EFFECTIVENESS OF USING VILDAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES UNDERGOING METFORMIN MONOTHERAPY WITH UNSATISFACTORY GLYCEMIC CONTROL

    Oct 1, 2018, 00:00

  • PND28 - A BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNITED KINGDOM.

    Oct 1, 2018, 00:00

  • PMS99 - ACUTE EFFECTS OF DYNAMIC STRETCHING AFTER WARM UP ON SPRINTING ABILITY AND AGILITY AMONG ADOLESCENT BASKETBALL PLAYERS

    Oct 1, 2018, 00:00

  • PMS96 - A DEMAND SURVEY ON PATIENT EDUCATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • Disclosure Information

    Oct 1, 2018, 00:00

  • PND105 - MULTIPLE SCLEROSIS- THE MAP OF PATIENT ACCESS TO DISEASE MODIFYING TREATMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PSY206 - COMPLEMENTARY AND ALTERNATIVE MEDICINE FOR PAIN- USAGE, OUTCOMES AND COST

    Oct 1, 2018, 00:00

  • PCN364 - EVALUATING PSYCHOMETRIC PROPERTIES OF UK EQ-5D-5L SCORING ALGORITHMS IN METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMD77 - ECONOMIC EVALUATION OF SCREENING AND PREVENTION STRATEGIES FOR OVARIAN CANCER- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN112 - BURDEN AND COSTS OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • HT5 - FINDINGS FROM THE FIRST FIVE YEARS OF THE UK NICE HST PROGRAM

    Oct 1, 2018, 00:00

  • PCN293 - WHAT IS THE VALUE OF REAL WORLD EVIDENCE IN ONCOLOGY IN HTA APPRAISALS IN ENGLAND, FRANCE, CANADA AND AUSTRALIA?

    Oct 1, 2018, 00:00

  • PHP366 - DEVELOPMENT OF THE UNIFIED SYSTEM OF ASSESSMENT OF LEVELS OF EVIDENCE AND GRADES OF RECOMMENDATIONS FOR THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PHP71 - HOW A NEW INNOVATION ASSESSMENT TOOL RELATES TO RECENT DRUG LAUNCHES FOR SPANISH NATIONAL ACCESS

    Oct 1, 2018, 00:00

  • PMH69 - QUALITY OF LIFE ACCORDING TO RESPONDER RATE IN OPIOID DEPENDENT ADULTS RECEIVING TREATMENT WITH BUPRENORPHINE DEPOT INJECTIONS (CAM2038) VERSUS SUBLINGUAL BUPRENORPHINE/NALOXONE

    Oct 1, 2018, 00:00

  • PHP28 - EXPLANATIONS FOR THE DIFFERENCES BETWEEN EFFECTS ON ADHERENCE OF VALUE-BASED HEALTH INSURANCE DESIGNS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCP8 - BENELUXA INITIATIVE- WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED?

    Oct 1, 2018, 00:00

  • PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PSY212 - TREATMENT CHARACTERISTICS, QUALITY OF LIFE AND SLEEP PERFORMANCE OF LOCALISED NEUROPATHIC PAIN PATIENTS IN THE PRIMARY CARE SETTING

    Oct 1, 2018, 00:00

  • PND20 - INCIDENCE AND TREATMENT OF PATIENTS WITH STATUS EPILEPTICUS- AN ANALYSIS OF GERMAN CLAIMS DATA

    Oct 1, 2018, 00:00

  • PHP334 - PHYSICIAN-RELATED FACTORS IN DOCTOR-SHOPPING- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONS

    Oct 1, 2018, 00:00

  • PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALY

    Oct 1, 2018, 00:00

  • PDB53 - EVALUATING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL, INCIDENCE OF SEVERE HYPOGLYCEMIA, AND LONG-TERM HEALTH ECONOMIC OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION- A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE US

    Oct 1, 2018, 00:00

  • PMD127 - FIRST DO NO HARM? EXPLORING THE INTERPRETATION OF NICE DIAGNOSTIC ASSESSMENTS WITH COST SAVINGS AND QALY LOSS

    Oct 1, 2018, 00:00

  • PIH50 - RESILIENCE AND ITS INFLUENCING FACTORS’ EFFECT ON TIMELY APPEARENCE OF 2ND AND 3RD PHASE OF LACTOGENESIS

    Oct 1, 2018, 00:00

  • PRM199 - STAKEHOLDER PERSPECTIVES ON CONDUCT AND USE OF PATIENT PREFERENCE STUDIES ALONG THE MEDICAL PRODUCT LIFECYCLE- RESULTS FROM FOCUS GROUPS

    Oct 1, 2018, 00:00

  • PRS1 - REAL-WORLD EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE- FINDINGS FROM AN OBSERVATIONAL CHART REVIEW OF A LARGE COHORT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PIN35 - COST-EFFECTIVENESS OF BEZLOTOXUMAB FOR THE PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCV111 - CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM PRESCRIBED ANTICOAGULANTS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP143 - ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES OF INNOVATIVE MEDICINES ACCORDING TO THE CATALAN HEALTH SERVICE STANDARDS- A QUALITATIVE ASSESSMENT

    Oct 1, 2018, 00:00

  • PSY117 - ASSESSMENT OF SOCIAL AND ECONOMIC BURDEN OF CHRONIC MYELOID LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PSY145 - IMPACT OF BIOSIMILAR ENTRY ON PRICE AND UPTAKE OF BRANDED BIOLOGICS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PCN97 - ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFE

    Oct 1, 2018, 00:00

  • PSY37 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF PROPIONIC ACIDEMIA

    Oct 1, 2018, 00:00

  • MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PMH53 - THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS- ANALYSIS OF REAL WORLD EVIDENCE FROM THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCN300 - MODERN TRENDS OF ORCHIECTOMY FOR PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PCN283 - IDENTIFYING THE KEY CHALLENGES AFFECTING THE REIMBURSEMENT OF CAR-T THERAPIES IN THE EU5 USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Oct 1, 2018, 00:00

  • PIN49 - THE COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN VERSUS CASPOFUNGIN FOR CANDIDEMIA AND INVASIVE CANDIDIASIS TREATMENT- AN EXPERIENCE FROM IRAN

    Oct 1, 2018, 00:00

  • PSS47 - A COHORT STUDY TO INVESTIGATE THE FACTORS ASSOCIATED WITH THE INTENTION TO USE ILLEGAL DRUG AMONG SAUDI STUDENTS

    Oct 1, 2018, 00:00

  • PMS16 - EFFECT OF BISPHOSPHONATES ON PERIPROSTHETIC BONE MINERAL DENSITY LOSS AFTER HIP ARTHROPLASTY- AN INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PMS72 - ASSOCIATION BETWEEN HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN AND TIME-TO-TOTAL KNEE REPLACEMENT SURGERY AMONG COMMERCIALLY-INSURED PATIENTS WITH KNEE OSTEOARTHRITIS IN THE UNITED STATES- A RETROSPECTIVE STUDY WI ...

    Oct 1, 2018, 00:00

  • PRS81 - PRESCRIBING PATTERN AND USE OF STEROIDS AMONG ASTHMATIC PATIENTS IN A TERTIARY CARE HOSPITAL

    Oct 1, 2018, 00:00

  • PSS41 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN TUNISIA

    Oct 1, 2018, 00:00

  • PSY136 - A COMPARISON OF PR REQUIREMENTS FOR ORPHAN DRUGS IN 25 MARKETS

    Oct 1, 2018, 00:00

  • PHP317 - IDENTIFYING THE CHANGES REQUIRED IN HEALTH TECHNOLOGY ASSESSMENT SYSTEMS IF OUTCOMES ARE TO BE OPTIMIZED IN A DIGITAL WORLD WHERE PERSONALIZED DATA AND PRECISION MEDICINE COLLIDE

    Oct 1, 2018, 00:00

  • PND137 - PATTERNS OF USE OF PROLONGED-RELEASE FAMPRIDINE AND PHYSIOTHERAPY AMONG PATIENTS WITH MS IN TWO LARGE MULTI-COUNTRY STUDY COHORTS

    Oct 1, 2018, 00:00

  • PHP113 - COMPARATIVE ANALYSIS OF BIOSIMILAR RITUXIMAB USAGE IN TREATING NON-HODGKIN LYMPHOMA AND RHEUMATOID ARTHRITIS- RESULTS FROM A MULTI-COUNTRY STUDY IN EUROPE

    Oct 1, 2018, 00:00

  • CV3 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN GERMANY- APPLYING THE EFFICIENCY THRESHOLD

    Oct 1, 2018, 00:00

  • PMD106 - COST-EFFECTIVENESS OF LONG-LASTING INSECTICIDE-NETS FOR THE PREVENTION OF MALARIA IN RURAL AND URBAN MALARIOUS AREAS

    Oct 1, 2018, 00:00

  • ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA

    Oct 1, 2018, 00:00

  • PIN62 - COST-EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINES IN A COHORT OF NEWBORNS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMS80 - PSORIATIC ARTHRITIS PREVALENCE IN PSORITIC PATIENTS- BRAZIL, CHILE AND COLOMBIA CASES

    Oct 1, 2018, 00:00

  • PUK23 - EVALUATION OF THE PROGRAM OF NEPHROPROTECTION IN PATIENTS WITH RENAL DISEASE OF A COLOMBIAN INSURANCE COMPANY

    Oct 1, 2018, 00:00

  • PRS90 - ASSOCIATION BETWEEN SEVERE, MODERATE AND MILD EXACERBATIONS WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN COPD PATIENTS

    Oct 1, 2018, 00:00

  • PHP256 - MACHINE LEARNING TO IDENTIFY REAL-WORLD PATIENT CHARACTERISTICS ASSOCIATED WITH LENGTH OF HOSPITALIZATION

    Oct 1, 2018, 00:00

  • PIH4 - HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH EXTREMELY PRETERM BIRTH IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE - THE QUESTIONNAIRE ” TOP SCORE "

    Oct 1, 2018, 00:00

  • PCN150 - COST-EFFECTIVENESS ANALYSIS OF PHARMACOKINETIC-GUIDED (PK) 5-FLUOROURACIL (5-FU) DOSING WHEN COMBINED WITH LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) CHEMOTHERAPY FOR ADVANCED PANCREAS CANCER

    Oct 1, 2018, 00:00

  • PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDY

    Oct 1, 2018, 00:00

  • PRM139 - CHOOSING THE RIGHT SOFTWARE FOR HTA ECONOMIC MODELS- A COMPARISON OF FOUR PROGRAMMES RECOMMENDED BY THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE

    Oct 1, 2018, 00:00

  • PMD49 - COST ANALYSIS OF USING THREE-DIMENSIONAL COMPLEX MAPPING CATHETER ABLATION VERSUS DRUG THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION IN TURKEY

    Oct 1, 2018, 00:00

  • PCN60 - REAL-WORLD OVERALL SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PRM86 - INFLAMMATORY BOWEL DISEASE AND THE COST FOR SOCIAL SECURITY SYSTEM- ESTIMATING THE PREVALENCE AND THE DISABILITY BURDEN AMONG THE ITALIAN WORKER

    Oct 1, 2018, 00:00

  • PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Oct 1, 2018, 00:00

  • PND98 - DETERMINING THE VALUE OF OCREVUS® (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • PRM252 - SIMULATED TREATMENT COMPARISON- IMPLICATIONS AND CHALLENGES OF AN ALTERNATIVE APPROACH TO ESTIMATING THE RELATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT COMPARATOR CHEMOTHERAPY TREATMENTS FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA ...

    Oct 1, 2018, 00:00

  • PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIA

    Oct 1, 2018, 00:00

  • PRS74 - ANTI-PNEUMOCOCCAL VACCINATION STRATEGY. STUDY AND PRELIMINARY RWD DECREASING GERIATRICS HOSPITAL ADMISSIONS AND CARE COSTS

    Oct 1, 2018, 00:00

  • PCN69 - BUDGET IMPACT OF SUBSTITUTING BIOSIMILAR TRASTUZUMAB (CT-P6) IN TREATING GASTRIC CANCER AND BREAST CANCER IN 28 EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination- A Systematic Review of the Literature

    Oct 1, 2018, 00:00

  • PMU100 - MAPPING BENEFIT-RISK DECISION-MAKING PROCESSES AND IDENTIFYING DECISION POINTS WITH THE POTENTIAL TO INCLUDE PATIENT PREFERENCE INFORMATION THROUGHOUT THE MEDICAL PRODUCT LIFECYCLE

    Oct 1, 2018, 00:00

  • PMD75 - THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION- EXPLORING THE ITALIAN NATIONAL HEALTH SYSTEM PERSPECTIVE AND CONSIDERING DIFFERENT PATIENTS RISK GROUPS

    Oct 1, 2018, 00:00

  • PMS6 - EFFECTIVENESS OF BIOSSIMILARS UNDER HOSPITAL PHARMACY MANAGEMENT POLICY

    Oct 1, 2018, 00:00

  • PDB57 - TRENDS IN USE OF DRUGS FOR DIABETES TREATMENT IN SLOVAKIA- REVIEW OF CONSUMPTION DATA FROM 2007 TILL 2017

    Oct 1, 2018, 00:00

  • PSY177 - HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH BETA-THALASSEMIA

    Oct 1, 2018, 00:00

  • PCV126 - A COST-EFFECTIVENESS THRESHOLD BASED ON THE MARGINAL RETURNS OF CARDIOVASCULAR HOSPITAL SPENDING

    Oct 1, 2018, 00:00

  • PMD21 - PRESSURE INJURIES IN PATIENTS WITH URINARY INCONTINENCE- EFFICACY OF REGENERA, A NEW MEDICAL DEVICE TESTED AT THE OSPEDALE MAGGIORE IN NOVARA

    Oct 1, 2018, 00:00

  • PSS10 - QUANTITATIVE ANALYSIS OF DIABETIC RETINOPATHY (DR) IN THE UK USING ROUTINELY COLLECTED DATA FROM SCREENING PROGRAMME AND HOSPITAL EYE SERVICE (HES) DATABASES

    Oct 1, 2018, 00:00

  • PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE- ISSUES AND WAYS FOR IMPROVEMENT

    Oct 1, 2018, 00:00

  • PCN117 - HEALTHCARE EXPENDITURES FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPAN

    Oct 1, 2018, 00:00

  • PRS2 - HEALTH OUTCOMES OF MATERNAL SMOKING DURING PREGNANCY AND POSTPARTUM PERIOD FOR THE MOTHER AND INFANT- AN UMBRELLA REVIEW

    Oct 1, 2018, 00:00

  • PGI42 - NON-PERSISTENCE WITH IMMUNOSUPPRESANT, ANTI-TUMOR NECROSIS FACTOR, AND ANTI-INTEGRIN AGENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE- A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANY

    Oct 1, 2018, 00:00

  • PND57 - THE COST-EFFECTIVENESS OF ALEMTUZUMAB IN THE MANAGEMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Oct 1, 2018, 00:00

  • PSY33 - FEASIBILITY OF EVALUATING THE BURDEN OF B-THALASSEMIA WITH GERMAN CLAIMS DATA

    Oct 1, 2018, 00:00

  • PCN308 - DO HEALTH TECHNOLOGY APPRAISALS HAVE AN IMPACT?- A COMPARISON OF CENTRALIZED AND REGIONAL APPROACHES

    Oct 1, 2018, 00:00

  • PIN48 - COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN COLOMBIAN ADULTS

    Oct 1, 2018, 00:00

  • PMD51 - COMPARISON OF COSTS AND OUTCOMES BETWEEN COBLATION TECHNOLOGY AND ELECTROCAUTERY FOLLOWING TONSILLECTOMY AND ADENOIDECTOMY PROCEDURES

    Oct 1, 2018, 00:00

  • PRM107 - CAN ACCOUNTING FOR MISSING DATA CAST DOUBT ON PREVIOUS CONCLUSIONS REEVALUATING A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)?

    Oct 1, 2018, 00:00

  • AD3 - EVALUATION OF THE “SOPHIA” ASTHMA PATIENT MANAGEMENT PROGRAM AT TWO YEARS

    Oct 1, 2018, 00:00

  • Vaccination Programs- Economic and Leadership Considerations

    Oct 1, 2018, 00:00

  • PMH30 - MENTAL DISORDERS AND MAJOR DEPRESSION- THE ECONOMIC ANALYSIS OF SOCIAL SECURITY COSTS IN ITALY

    Oct 1, 2018, 00:00

  • PRM243 - NETWORK META-ANALYSES ON SURVIVAL DATA- A COMPARISON AND GUIDANCE FOR DIFFERENT METHODOLOGIES

    Oct 1, 2018, 00:00

  • PCN276 - MANAGED ACCESS AGREEMENTS UNDER THE CANCER DRUGS FUND (CDF)- KEY METRICS AND DRIVERS

    Oct 1, 2018, 00:00

  • PHP356 - COMPARATIVE ANALYSIS BETWEEN OLD AND NEW ITALIAN INNOVATION RATING SYSTEM

    Oct 1, 2018, 00:00

  • PSY36 - CLINICAL BURDEN OF CHRONIC GRAFT VERSUS HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW OF INCIDENCE AND DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PIN63 - A COST-MINIMIZATION MODEL TO EVALUATE THE IMPACT OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS IN HOSPITALIZED ADULTS IN SPAIN

    Oct 1, 2018, 00:00

  • PHP7 - DIGITALIZATION AND CUSTOMER-RESPONSIVE SECONDARY CARE SERVICES POTENTIALLY FREE HEALTH CARE CAPACITY- PREDICTED MONETARY BENEFITS OF VIRTUAL HOSPITAL 2.0

    Oct 1, 2018, 00:00

  • PCN168 - COST-EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMD119 - SYSTEMATIC REVIEW ON CLINICAL OUTCOMES OF ULTRASONIC TECHNOLOGY FOR PATIENTS UNDERGOING COLORECTAL ONCOLOGY PROCEDURES

    Oct 1, 2018, 00:00

  • PND80 - AN OBSERVATIONAL STUDY OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS IN FRANCE- FIRST INTERIM ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION FROM THE BRIO STUDY

    Oct 1, 2018, 00:00

  • PMS37 - INDIRECT COSTS OF VERTEBRAL ALGIC SYNDROME

    Oct 1, 2018, 00:00

  • PMD139 - VALUE-BASED PROCUREMENT OF MEDICAL EQUIPMENT IN EUROPE – DID THE 2014 EU DIRECTIVE INFLUENCE TENDERING PRACTICES AND EVIDENCE DEMAND?

    Oct 1, 2018, 00:00

  • PSY65 - REAL-WORLD DATA ANALYSIS OF US CLAIMS DATA ON COAGULATION FACTOR IX DISPENSATION AND EXPENDITURES IN PATIENTS WITH SEVERE HEMOPHILIA B- STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE PRODUCTS

    Oct 1, 2018, 00:00

  • PIN109 - EVALUATION OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING HIV/AIDS AMONG PREGNANT WOMEN AND THEIR PARTNERS INVOLVED IN PREVENTION MOTHER-TO-CHILD TRANSMISSION (PMTCT) PROGRAMS IN MALAWI.

    Oct 1, 2018, 00:00

  • PIN68 - COST-EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMU16 - DISPENSING PATTERNS OF VACCINES IN A PRIVATE HEALTHCARE SETTING IN SOUTH AFRICA

    Oct 1, 2018, 00:00

  • PMD142 - WHAT DISCOURAGES ELDERLY USE OF INSULIN-INFUSION PUMPS IN JAPAN?

    Oct 1, 2018, 00:00

  • PRM210 - METHODS USED TO IDENTIFY PATIENT REPORTED OUTCOME MEASURES IN VASCULAR DISEASES

    Oct 1, 2018, 00:00

  • PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

    Oct 1, 2018, 00:00

  • PCN265 - END OF LIFE CANCER CHEMOTHERAPY- A RETROSPECTIVE STUDY DURING INTENSIVE CARE UNIT (ICU) STAY

    Oct 1, 2018, 00:00

  • PCN386 - QUALITY OF LIFE OF CAREGIVERS OF CANCER PATIENTS BEFORE AND AFTER PATIENT ADMISSION TO AN INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PHP207 - ASSESSMENT OF PHARMACIST MEDICATION CONSULTATION IN COMMUNITY PHARMACIES LOCATED IN TEHRAN

    Oct 1, 2018, 00:00

  • PHP275 - ORPHAN MEDICINAL PRODUCTS GIVEN AN INITIAL NEGATIVE RECOMMENDATION BY NICE'S STA PROCESS BUT APPROVED FOLLOWING RE-EVALUATION IN ENGLAND

    Oct 1, 2018, 00:00

  • PSY163 - IDENTIFICATION OF KEY ORPHAN DRUG ATTRIBUTES IN PREDICTING THE EXPECTED LEVEL OF PAYER MANAGEMENT IN THE US AND EU3

    Oct 1, 2018, 00:00

  • PUK9 - NETWORK META-ANALYSIS OF TREATMENTS IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL-CELL CARCINOMA WITH INTERMEDIATE TO POOR PROGNOSIS

    Oct 1, 2018, 00:00

  • PHP299 - THREE YEARS OF SINATS

    Oct 1, 2018, 00:00

  • PMU65 - COST-MINIMIZATION ANALYSIS OF SMOFKABIVEN® CENTRAL FOR ADULT PATIENTS WITH IMPOSSIBLE, INSUFFICIENT OR CONTRAINDICATED ORAL OR ENTERAL NUTRITION VERSUS STANDARD ENDOVASCULAR TREATMENT IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PRM74 - CLINICAL OUTCOME ASSESSMENTS IN DRUG APPROVALS- A REVIEW OF LABEL CLAIMS IN THE UNITED STATES AND EUROPE (2013-2017)

    Oct 1, 2018, 00:00

  • PSS45 - A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

    Oct 1, 2018, 00:00

  • PRM83 - COMPARATIVE ASSSESMENT OF ORAL ANTIDIABETIC DRUG-MEDIATED GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS BETWEEN TWO DIFFERENT REAL-WORLD DATABASES

    Oct 1, 2018, 00:00

  • PRM202 - COMPARING THE EQ-5D-5L CROSSWALKS AND VALUE SETS FOR ENGLAND, THE NETHERLANDS AND SPAIN- DO CONCLUSIONS CHANGE?

    Oct 1, 2018, 00:00

  • PRS72 - A COST ESTIMATION OF MANAGEMENT OF ALLERGIC ASTHMA IN ITALY

    Oct 1, 2018, 00:00

  • PND121 - UTILITIES ASSOCIATED WITH ATTRIBUTES OF MIGRAINE PREVENTIVE TREATMENTS- ROUTE OF ADMINISTRATION AND ADVERSE EVENTS

    Oct 1, 2018, 00:00

  • PMS105 - EXAMINATION OF CORE TRAINING PROGRAM ON THE CHANGE OF LOW BACK PAIN, MUSCLE STRENGTH AND LUMBAR MOTOR CONTROLL AMONG PROFESSIONAL FIREFIGHTERS

    Oct 1, 2018, 00:00

  • PUK21 - COST UTILITY ANALYSIS OF END STAGE RENAL DISEASE TREATMENT IN MINISTRY OF HEALTH DIALYSIS CENTRES, MALAYSIA- HAEMODIALYSIS VERSUS CONTINUOUS AMBULATORY PERITONEAL DIALYSIS

    Oct 1, 2018, 00:00

  • PCN98 - PALLIATIVE TREATMENT AND ITS COST IN THE LAST SIX MONTHS OF LIFE FOR METASTATIC COLORECTAL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PMD10 - PREVALENCE OF UNCONTROLLED BLOOD PRESSURE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIA

    Oct 1, 2018, 00:00

  • PMS68 - HOSPITAL PHARMACY CENTRALIZED PROCESS FOR HOSPITAL-WIDE MANAGEMENT OF BIOSSIMILARS USE AND ITS EFFICIENCY

    Oct 1, 2018, 00:00

  • PSY119 - TREATMENT PATTERN ANALYSIS AND HEALTHCARE RESOURCE CONSUMPTION ON PATIENTS AFFECTED BY PSORIASIS IN APULIA REGION (ITALY).

    Oct 1, 2018, 00:00

  • PHP310 - COMPARISON OF THE HEALTH TECHNOLOGY ASSESSMENT OFFICES OF HUNGARY AND POLAND BASED ON OBJECTIVE CRITERIA

    Oct 1, 2018, 00:00

  • PDB118 - SYSTEMATIC EDUCATION IN PATIENTS WITH T2DM SIGNIFICANTLY IMPROVES ADHERENCE TO THE TREATMENT. THE ADVICE STUDY

    Oct 1, 2018, 00:00

  • PRM13 - THE FLAWED RECOMMENDATIONS OF THE SECOND PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE

    Oct 1, 2018, 00:00

  • PCN246 - EVOLUTION OF ONCOLYTICS CONSUMPTION IN PORTUGAL OVER TEN YEARS

    Oct 1, 2018, 00:00

  • PRS93 - THE HEALTH-RELATED QUALITY OF LIFE BURDEN OF PEANUT ALLERGY IN ADULTS, ADOLESCENTS AND CHILDREN IN THE UK

    Oct 1, 2018, 00:00

  • PMH25 - EARLY ADMINISTRATION OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN ACUTE INPATIENTS WITH SCHIZOPHRENIA REDUCES THE COST OF HOSPITALIZATION

    Oct 1, 2018, 00:00

  • PMD152 - HEALTHCARE RESOURCE UTILIZATION, COMPLICATIONS AND COSTS FOR OPEN REDUCTION INTERNAL FIXATION OF THE FEMUR, TIBIA AND FIBULA

    Oct 1, 2018, 00:00

  • PRM112 - INCORPORATION OF ANTI-CANCER DRUGS ADVERSE EVENTS IN HEALTH ECONOMIC OPINIONS OF THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Oct 1, 2018, 00:00

  • PMD116 - UTILISATION AND ECONOMIC BURDEN OF FLOWABLE HEMOSTATIC AGENTS IN GERMAN HOSPITALS- A REAL-WORLD PATIENT CHART REVIEW STUDY

    Oct 1, 2018, 00:00

  • PSS49 - EPIDEMIOLOGY AND TREATMENT PATTERNS IN ADULT PATIENTS WITH ATOPIC DERMATITIS- ANALYSIS OF LONGITUDINAL DATA FROM THE GERMAN STATUTORY HEALTH INSURANCE SYSTEM

    Oct 1, 2018, 00:00

  • PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PRM26 - TIME TO DETERIORATION (TTD) IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN NSCLC PATIENTS- A REVIEW OF DEFINITIONS

    Oct 1, 2018, 00:00

  • PSY160 - REAL WORLD TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PULMONARY ARTERIAL HYPERTENSION IN BRAZIL- A PUBLIC HEALTHCARE DATABASE STUDY

    Oct 1, 2018, 00:00

  • PMS84 - COMPARISON OF HTA ASSESSMENTS OF SARILUMAB IN DIFFERENT SUBPOPULATIONS FOR RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PHP34 - TIME ANALYSIS OF THE DRUG APPROVAL PROCESS IN EUROPE

    Oct 1, 2018, 00:00

  • PRS79 - MODELING THE POPULATION YEARS OF LIFE SAVED BY INTRODUCING A REDUCED-RISK PRODUCT IN THE U.S. AND IN JAPAN

    Oct 1, 2018, 00:00

  • PCN289 - HOW ACCELARATED IS PATIENTS’ ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG’S FUND IN ENGLAND?

    Oct 1, 2018, 00:00

  • PCN149 - COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPAN

    Oct 1, 2018, 00:00

  • PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?

    Oct 1, 2018, 00:00

  • PSS19 - IMPORTANCE OF THE OUT-OF-POCKET COST FOR ATOPIC DERMATITIS AFFECTED ADULTS

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62 (current)
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • »